- Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic markerRajan Dewar
Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston MA, USA
Cancer Biol Ther 11:552-8. 2011..Additionally, proteasomal inhibition by bortezomib may be a promising therapeutic option in Philadelphia-positive ALL, where FoxO3 is downregulated...
- Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathologyRajan Dewar
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
Arch Pathol Lab Med 135:422-9. 2011....